Literature DB >> 29472058

PD-L1 Expression in Small Cell Lung Cancer.

Yuto Yasuda1, Hiroaki Ozasa1, Young Hak Kim2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472058     DOI： 10.1016/j.jtho.2017.10.013

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  11 in total

1.  Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.

Authors:  Ryusuke Hatae; Kenji Chamoto; Young Hak Kim; Kazuhiro Sonomura; Kei Taneishi; Shuji Kawaguchi; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Maryam Akrami; Sidonia Fagarasan; Izuru Masuda; Yasushi Okuno; Fumihiko Matsuda; Toyohiro Hirai; Tasuku Honjo
Journal:  JCI Insight       Date:  2020-01-30

2.  Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Authors:  Shirish M Gadgeel; Nathan A Pennell; Mary Jo Fidler; Balazs Halmos; Philip Bonomi; James Stevenson; Bryan Schneider; Ammar Sukari; Jaclyn Ventimiglia; Wei Chen; Cathy Galasso; Antoinette Wozniak; Julie Boerner; Gregory P Kalemkerian
Journal:  J Thorac Oncol       Date:  2018-07-17       Impact factor: 15.609

Review 3.  PD-L1 as a biomarker of response to immune-checkpoint inhibitors.

Authors:  Deborah Blythe Doroshow; Sheena Bhalla; Mary Beth Beasley; Lynette M Sholl; Keith M Kerr; Sacha Gnjatic; Ignacio I Wistuba; David L Rimm; Ming Sound Tsao; Fred R Hirsch
Journal:  Nat Rev Clin Oncol       Date:  2021-02-12       Impact factor: 66.675

Review 4.  Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.

Authors:  Yaru Tian; Xiaoyang Zhai; Anqin Han; Hui Zhu; Jinming Yu
Journal:  J Hematol Oncol       Date:  2019-06-28       Impact factor: 17.388

5.  IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer.

Authors:  Chengliang Huang; Gregory N Gan; Jun Zhang
Journal:  J Hematol Oncol       Date:  2020-06-05       Impact factor: 17.388

Review 6.  [Immune Characteristics of Small Cell Lung Cancer].

Authors:  Yan Zhu; Shikai Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-10-20

7.  In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.

Authors:  Yusuke Tomita; Bryan Oronsky; Nacer Abrouk; Pedro Cabrales; Tony R Reid; Min-Jung Lee; Akira Yuno; Jonathan Baker; Sunmin Lee; Jane B Trepel
Journal:  Transl Lung Cancer Res       Date:  2021-01

8.  Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer.

Authors:  Shili Yu; Meng Jia; Yuemin Li; Ping-Li Sun; Hongwen Gao
Journal:  Front Med (Lausanne)       Date:  2021-01-25

9.  Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Emmanuel Acheampong; Afaf Abed; Michael Morici; Samantha Bowyer; Benhur Amanuel; Weitao Lin; Michael Millward; Elin S Gray
Journal:  Cells       Date:  2020-10-31       Impact factor: 6.600

Review 10.  Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer.

Authors:  Ivy Riano; Shruti R Patel; Stephen V Liu; Narjust Duma
Journal:  Clin Pract       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.